Bessemer Group Inc. Has $17.32 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

Bessemer Group Inc. trimmed its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 26.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,600 shares of the company’s stock after selling 100,620 shares during the period. Bessemer Group Inc.’s holdings in Prestige Consumer Healthcare were worth $17,323,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after buying an additional 250 shares in the last quarter. First Horizon Corp bought a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth about $32,000. Hantz Financial Services Inc. boosted its position in shares of Prestige Consumer Healthcare by 373.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after acquiring an additional 538 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Prestige Consumer Healthcare in the second quarter valued at about $46,000. Finally, Geneos Wealth Management Inc. raised its position in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity

In other news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Up 1.4%

Shares of PBH opened at $66.48 on Friday. The business’s fifty day moving average price is $63.19 and its two-hundred day moving average price is $64.06. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 2.06 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 52 week low of $57.25 and a 52 week high of $90.04. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.51 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company’s revenue was down 2.4% compared to the same quarter last year. During the same period last year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBH has been the topic of a number of recent research reports. Oppenheimer decreased their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Jefferies Financial Group dropped their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $80.60.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Management highlighted progress restoring Clear Eyes supply and said availability is improving, which supports a rebound in that brand’s sales going forward. Prestige Consumer Healthcare narrows fiscal 2026 revenue outlook to $1.1B while advancing Clear Eyes supply recovery
• Positive Sentiment: The company narrowed and finalized its fiscal‑2026 revenue outlook to about $1.1 billion, which reduces uncertainty around full‑year expectations and may reassure investors. Prestige Consumer Healthcare Q3 revenue tops estimates, narrows guidance
• Neutral Sentiment: Management posted the full slide deck and call transcript; these provide detail on segment trends, margins and working‑capital dynamics for investors doing deeper diligence. Q3 2026 Earnings Call Transcript
• Negative Sentiment: Q3 results showed a small EPS miss: $1.14 reported vs. ~$1.16 consensus, and revenue of ~$283.4M was down roughly 2.4% year‑over‑year—factors that are short‑term headwinds for the stock. Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
• Negative Sentiment: Fiscal‑2026 EPS guidance was set at 4.54 (company’s figure), essentially flat-to-slightly below some sell‑side consensus (~4.55), leaving limited upside in near‑term estimates. Press release: Third Quarter and Year-to-Date Fiscal 2026 Results

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).